{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:28:41Z","timestamp":1783020521583,"version":"3.54.6"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japanese Agency for Medical Research and Development","award":["JP23yk0126023"],"award-info":[{"award-number":["JP23yk0126023"]}]},{"name":"Japanese Agency for Medical Research and Development","award":["JP24yk0126029"],"award-info":[{"award-number":["JP24yk0126029"]}]},{"name":"Japanese Agency for Medical Research and Development","award":["JP25lk0221214"],"award-info":[{"award-number":["JP25lk0221214"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Submacular hemorrhage (SMH), which may arise from age-related macular degeneration, retinal arterial macroaneurysm, and other causes, can result in severe vision loss and central visual field impairment. Although tissue plasminogen activator (tPA) is used off-label to treat SMH in many countries, no formulation has been approved for this indication. Because early intervention is critical when tPA is used for SMH, limited access to centers that can provide this treatment may delay care and reduce treatment opportunities. Decentralized clinical trials (DCTs) reduce or eliminate the need for participants to travel to trial sites. We therefore designed the investigator-initiated SACLA trial to evaluate subretinal tPA for SMH. The DCT framework is intended to reduce logistical barriers related to the disease severity and rarity. The SACLA trial is a phase II multicenter, open-label, single-arm surgical study with a pre-post comparison design (jRCT2071250003). Twenty eligible participants will undergo pars plana vitrectomy followed by subretinal injection of 0.1 mL (8,000 IU) of tPA. Participants will remain hospitalized at the trial site until the primary outcome, change in central foveal thickness (CFT) from baseline at Week 1, is assessed. Thereafter, follow-up visits will be conducted at either the trial site or partner sites within the DCT framework. Secondary efficacy outcomes include change in CFT from baseline, presence of a foveal hemorrhage measuring at least 1 disc diameter, best-corrected visual acuity (BCVA), and change in BCVA from baseline at Weeks 4 and 12. Adverse events will be collected throughout the 12-week observation period to assess safety. The protocol and related study documents were reviewed and approved by the Saga University Hospital Institutional Review Board. This study is designed to generate prospective evidence on the feasibility, short-term anatomical response, and safety of subretinal tPA for SMH.<\/jats:p>","DOI":"10.1371\/journal.pone.0353127","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:06:25Z","timestamp":1783015585000},"page":"e0353127","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protocol for the SACLA trial: Efficacy and safety of subretinal monteplase for submacular hemorrhage in a phase II single-arm multicenter decentralized clinical trial"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7653-2818","authenticated-orcid":true,"given":"Noriko","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kobayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouta","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Shinkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7152-5443","authenticated-orcid":true,"given":"Takuma","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Mitsutake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Hoshiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Takamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Terasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3769-7609","authenticated-orcid":true,"given":"Toshihiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0806-6146","authenticated-orcid":true,"given":"Atsunobu","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Kadonosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9887-3210","authenticated-orcid":true,"given":"Makoto","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Todaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh-Hei","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Enaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"3","key":"pone.0353127.ref001","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00006982-199616030-00001","article-title":"Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration","volume":"16","author":"RL Avery","year":"1996","journal-title":"Retina"},{"issue":"9","key":"pone.0353127.ref002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274508","article-title":"Differences in clinical characteristics and treatment outcomes of submacular hemorrhage caused by age-related macular degeneration and retinal macroaneurysms: A multicenter survey from the Japan Clinical Retina Study (J-CREST) group","volume":"17","author":"T Kimura","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"pone.0353127.ref003","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0039-6257(97)00089-1","article-title":"Pathophysiology and management of subretinal hemorrhage","volume":"42","author":"MA Hochman","year":"1997","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"pone.0353127.ref004","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000027400","article-title":"Natural history of macular subretinal hemorrhage in age-related macular degeneration","volume":"213","author":"A Scupola","year":"1999","journal-title":"Ophthalmologica"},{"key":"pone.0353127.ref005","unstructured":"\u201cMcGowan GF, Steel D, Yorston D. AMD with submacular hemorrhage: new insights from a population-based study. In: Assoc Res Vis Ophthalmol Annu Meet. 2014."},{"issue":"3","key":"pone.0353127.ref006","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41433-018-0239-4","article-title":"Incidence of submacular haemorrhage (SMH) in Scotland: a Scottish Ophthalmic Surveillance Unit (SOSU) study","volume":"33","author":"A Al-Hity","year":"2019","journal-title":"Eye (Lond)"},{"issue":"6","key":"pone.0353127.ref007","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/0002-9394(82)90301-4","article-title":"Experimental subretinal hemorrhage in rabbits","volume":"94","author":"H Glatt","year":"1982","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"pone.0353127.ref008","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-9394(14)75575-8","article-title":"Factors prognostic of visual outcome in patients with subretinal hemorrhage","volume":"109","author":"SR Bennett","year":"1990","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"pone.0353127.ref009","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0021-5155(03)00104-7","article-title":"Visual prognosis for symptomatic retinal arterial macroaneurysm","volume":"47","author":"T Tonotsuka","year":"2003","journal-title":"Jpn J Ophthalmol"},{"issue":"10","key":"pone.0353127.ref010","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1001\/archopht.116.10.1326","article-title":"Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator","volume":"116","author":"M Ohji","year":"1998","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"pone.0353127.ref011","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s10384-006-0369-2","article-title":"Surgical excision of retinal macroaneurysms with submacular hemorrhage","volume":"50","author":"Y Oie","year":"2006","journal-title":"Jpn J Ophthalmol"},{"issue":"2","key":"pone.0353127.ref012","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10792-015-0102-6","article-title":"Treatment of massive subretinal hematoma associated with age-related macular degeneration using vitrectomy with intentional giant tear","volume":"36","author":"E Isizaki","year":"2016","journal-title":"Int Ophthalmol"},{"issue":"1","key":"pone.0353127.ref013","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/17469899.2020.1725474","article-title":"Update on medical and surgical management of submacular hemorrhage","volume":"15","author":"AQ Lu","year":"2020","journal-title":"Expert Review of Ophthalmology"},{"issue":"5","key":"pone.0353127.ref014","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/archopht.1991.01080050139046","article-title":"Fibrin directs early retinal damage after experimental subretinal hemorrhage","volume":"109","author":"CA Toth","year":"1991","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"pone.0353127.ref015","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0161-6420(95)30858-5","article-title":"Submacular hemorrhage removal","volume":"102","author":"JI Lim","year":"1995","journal-title":"Ophthalmology"},{"issue":"1","key":"pone.0353127.ref016","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.survophthal.2015.04.004","article-title":"Submacular hemorrhage in neovascular age-related macular degeneration: a synthesis of the literature","volume":"61","author":"D Stanescu-Segall","year":"2016","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"pone.0353127.ref017","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9394(14)70274-0","article-title":"Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid","volume":"121","author":"M Kamei","year":"1996","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"pone.0353127.ref018","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0002-9394(14)71037-2","article-title":"Focal macular electroretinogram before and after drainage of macular subretinal hemorrhage","volume":"123","author":"H Terasaki","year":"1997","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"pone.0353127.ref019","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00417-011-1649-1","article-title":"Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator","volume":"249","author":"T Mizutani","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"pone.0353127.ref020","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1097\/IAE.0b013e318287d99d","article-title":"Comparison of pneumatic displacement for submacular hemorrhages with gas alone and gas plus tissue plasminogen activator","volume":"33","author":"M Fujikawa","year":"2013","journal-title":"Retina"},{"issue":"1","key":"pone.0353127.ref021","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ophtha.2014.07.027","article-title":"Displacement of submacular hemorrhages in age-related macular degeneration with subretinal tissue plasminogen activator and air","volume":"122","author":"K Kadonosono","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"pone.0353127.ref022","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ajo.2014.12.020","article-title":"Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator","volume":"159","author":"S Kimura","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"pone.0353127.ref023","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00417-014-2861-6","article-title":"Subretinal injection of recombinant tissue plasminogen activator for submacular hemorrhage associated with ruptured retinal arterial macroaneurysm","volume":"253","author":"M Inoue","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"pone.0353127.ref024","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00417-018-4059-9","article-title":"Flattening of retinal pigment epithelial detachments after pneumatic displacement of submacular hemorrhages secondary to age-related macular degeneration","volume":"256","author":"M Kimura","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"pone.0353127.ref025","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10384-019-00679-2","article-title":"Outcomes of vitrectomy combined with subretinal tissue plasminogen activator injection for submacular hemorrhage associated with polypoidal choroidal vasculopathy","volume":"63","author":"S Kimura","year":"2019","journal-title":"Jpn J Ophthalmol"},{"key":"pone.0353127.ref026","doi-asserted-by":"crossref","first-page":"100556","DOI":"10.1016\/j.ajoc.2019.100556","article-title":"Complication associated with intravitreal injection of tissue plasminogen activator for treatment of submacular hemorrhage due to rupture of retinal arterial macroaneurysm","volume":"16","author":"E Tsuiki","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"pone.0353127.ref027","doi-asserted-by":"crossref","first-page":"2963822","DOI":"10.1155\/2021\/2963822","article-title":"Long-Term Outcome Of Eyes With Vitrectomy For Submacular And\/or Vitreous Hemorrhage In Neovascular Age-related Macular Degeneration","volume":"2021","author":"S Kawakami","year":"2021","journal-title":"J Ophthalmol"},{"issue":"3","key":"pone.0353127.ref028","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s10384-022-00910-7","article-title":"Postoperative follow-up of submacular hemorrhage displacement treated with vitrectomy and subretinal injection of tissue plasminogen activator: ultrawide-field fundus autofluorescence imaging in gas-filled eyes","volume":"66","author":"Y Fukuda","year":"2022","journal-title":"Jpn J Ophthalmol"},{"issue":"11","key":"pone.0353127.ref029","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1097\/IAE.0000000000003885","article-title":"Predictors of 3-month and 1-year visual outcomes after vitrectomy with subretinal tissue plasminogen activator injection for submacular hemorrhage","volume":"43","author":"M Miki","year":"2023","journal-title":"Retina"},{"key":"pone.0353127.ref030","doi-asserted-by":"crossref","first-page":"1081150","DOI":"10.3389\/fpubh.2022.1081150","article-title":"Decentralized clinical trials (DCTs): a few ethical considerations","volume":"10","author":"C Petrini","year":"2022","journal-title":"Front Public Health"},{"issue":"4","key":"pone.0353127.ref031","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cpt.3009","article-title":"Design and execution of sustainable decentralized clinical trials","volume":"114","author":"P Singh","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"pone.0353127.ref032","doi-asserted-by":"crossref","first-page":"41","DOI":"10.12793\/tcp.2024.32.e2","article-title":"The landscape of decentralized clinical trials (DCTs): focusing on the FDA and EMA guidance","volume":"32","author":"J Park","year":"2024","journal-title":"Transl Clin Pharmacol"},{"issue":"1","key":"pone.0353127.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pdig.0001191","article-title":"Decentralized clinical trials: a comprehensive analysis of trends, technologies, and global challenges","volume":"5","author":"S Kijewski","year":"2026","journal-title":"PLOS Digit Health"},{"issue":"1","key":"pone.0353127.ref034","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-023-02693-7","article-title":"Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective","volume":"18","author":"M Ghadessi","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"pone.0353127.ref035","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/cas.70237","article-title":"Realizing equitable precision oncology via remote participation: Japan\u2019s first fully decentralized trial (WJOG15221M)","volume":"117","author":"H Taniguchi","year":"2026","journal-title":"Cancer Sci"},{"key":"pone.0353127.ref036","author":"Japan MHLW","year":"2024"},{"key":"pone.0353127.ref037","author":"Final NIH","year":"2016"},{"issue":"3","key":"pone.0353127.ref038","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/cts.12447","article-title":"Final NIH policy on the use of a single institutional review board for multisite research","volume":"10","author":"VM Gordon","year":"2017","journal-title":"Clin Transl Sci"},{"issue":"6","key":"pone.0353127.ref039","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jjco\/hyac034","article-title":"Overview of the ethical guidelines for medical and biological research involving human subjects in Japan","volume":"52","author":"J Eba","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"pone.0353127.ref040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3999\/jscpt.49.159","article-title":"Survey on centralization of research ethics review for multicenter clinical trials in Japan","volume":"49","author":"A Inano","year":"2018","journal-title":"Jpn J Clin Pharmacol Ther"},{"issue":"1","key":"pone.0353127.ref041","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13063-021-05966-3","article-title":"Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial","volume":"23","author":"TL Jackson","year":"2022","journal-title":"Trials"},{"issue":"4","key":"pone.0353127.ref042","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0161-6420(02)01979-6","article-title":"Retinal toxicity of intravitreal tissue plasminogen activator: case report and literature review","volume":"110","author":"S-N Chen","year":"2003","journal-title":"Ophthalmology"},{"issue":"7","key":"pone.0353127.ref043","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1111\/cas.15792","article-title":"First experience of a fully decentralized clinical trial: The dawn of a new era in oncology","volume":"114","author":"H Taniguchi","year":"2023","journal-title":"Cancer Sci"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0353127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:06:36Z","timestamp":1783015596000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0353127"}},"subtitle":[],"editor":[{"given":"Alejandro","family":"Torrado Pacheco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0353127","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]}}}